title: Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
abstract: The blockade of VEGF pathway has been clinically validated as an initial treatment for renal cell carcinoma (RCC). Angiopoietin-2 (Ang-2) has been indicated as a key regulator for angiogenesis escape. The effect of a novel bispecific antibody (A2V CrossMab) against both Ang-2 and VEGF was investigated in comparison with either factor. A2V CrossMab significantly reduced tumor volume, vessel density, and interstitial fluid pressure compared to either monotherapy of anti-VEGF or anti-Ang-2. Host-derived angiogenesis-related genes have been significantly down-regulated in A2V CrossMab group. These data demonstrate that A2V CrossMab has additive anti-tumor effect for the treatment of RCC.
authors.affiliation: a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.|b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.|c Department of Urology , Kitasato University School of Medicine , Kanagawa , Japan.
authors.forename: Hideharu
authors.initials: H
authors.lastname: Bessho
authors.affiliation: a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.|b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
authors.forename: Bernice
authors.initials: B
authors.lastname: Wong
authors.affiliation: a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.|b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
authors.forename: Dachuan
authors.initials: D
authors.lastname: Huang
authors.affiliation: a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.|b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
authors.forename: Jing
authors.initials: J
authors.lastname: Tan
authors.affiliation: a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.|b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
authors.forename: Choon Kiat
authors.initials: CK
authors.lastname: Ong
authors.affiliation: c Department of Urology , Kitasato University School of Medicine , Kanagawa , Japan.
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Iwamura
authors.affiliation: d Roche Pharma Research & Early Development , Translational Medicine Hub , Singapore , Singapore.
authors.forename: Stefan
authors.initials: S
authors.lastname: Hart
authors.affiliation: d Roche Pharma Research & Early Development , Translational Medicine Hub , Singapore , Singapore.
authors.forename: Markus
authors.initials: M
authors.lastname: Dangl
authors.affiliation: e Roche Diagnostics GmbH , Penzberg , Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Thomas
authors.affiliation: a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.|b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.|f Cancer Science Institute of Singapore , National University of Singapore , Singapore.
authors.forename: Bin Tean
authors.initials: BT
authors.lastname: Teh
mesh_terms: D042702:Angiopoietin-2 / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics; D016000:Cluster Analysis; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D042702:Angiopoietin-2; D018033:Antibodies, Bispecific; D042461:Vascular Endothelial Growth Factor A
keywords: Angiopoietin; Anti-angiogenic therapy; Interstitial fluid pressure; Renal cell carcinoma; VEGF